Oncology News and Research

RSS

Oncology, meaning bulk, mass, or tumor, and the suffix ''-logy'', meaning "study of") is a branch of medicine that deals with tumors (cancer). A medical professional who practices oncology is an ''oncologist''.

MGH, Veridex establish research center of excellence on circulating tumor cell technologies

Massachusetts General Hospital (MGH) has entered into a collaborative agreement with Veridex LLC to establish a center of excellence in research on circulating tumor cell (CTC) technologies. The overall goal of the agreement is to develop and commercialize novel technologies for capturing and characterizing CTCs, solid tumor cells found at extremely low levels in the bloodstream, which may offer a key to noninvasive characterization of cancer and potentially to early detection.

4 Jan 2011

CDK1 protein deactivates EZH2 enzyme that causes cancer spread

By sticking a chemical group to it at a specific site, a protein arrests an enzyme that may worsen and spread cancer, an international research team led by scientists at The University of Texas MD Anderson Cancer Center reports in the January issue of Nature Cell Biology.

4 Jan 2011

Los Angeles Magazine declares LA BioMed physicians as 2011 Southern California Super Doctors

A select 40 physician-researchers at Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center were named 2011 Southern California Super Doctors in the January issue of Los Angeles Magazine.

4 Jan 2011

EDAP reduces outstanding debt by $4.6 million

EDAP TMS SA, the global leader in therapeutic ultrasound, announced today that it entered into agreements with certain holders of its senior debentures and warrants to redeem part of EDAP's outstanding convertible debt and cancel some of its outstanding warrants. Pursuant to these agreements, the Company issued 1,441,743 ordinary shares in the form of American Depositary Shares in exchange for 4,558 senior debentures (equivalent to USD 4,558,000) and 986,965 warrants, reducing the current outstanding debt by USD 4.6 million to USD 10.5 million.

3 Jan 2011

EpiCept regains compliance with continued listing requirement of Nasdaq Capital Market

EpiCept Corporation today announced that it has received notification from the Nasdaq Listing Qualifications Department that it has regained compliance with the continued listing requirement of the Nasdaq Capital Market that it maintain a minimum market value of its listed securities of at least $35 million pursuant to Listing Rule 5550(b)(2).

3 Jan 2011

Children more likely to suffer from appendicitis in areas with few pediatricians

Children who live in areas with fewer pediatricians are more likely to suffer life-threatening ruptures of the appendix than those in areas with more pediatricians, even when accounting for other factors such as the number of hospitals, imaging technology, insurance coverage and the number of surgeons in an area, according to a study from the Johns Hopkins Children's Center.

30 Dec 2010

Enrollment commences in belinostat-Tarceva combination trial for NSCLC

Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations with a primary focus in oncology, and Topotarget A/S announced today that the first patient has been dosed in an Investigator Initiated Trial of belinostat in combination with Tarceva® for patients with Non-Small Cell Lung Cancer (NSCLC).

30 Dec 2010

Clinical Data closes sale of genetic, pharmacogenomic testing and biomarker development business

Clinical Data, Inc. today announced that the Company has closed the sale of its genetic and pharmacogenomic testing and biomarker development business to Transgenomic, Inc. for $15.5 million. The sale completes Clinical Data's transformation into a pharmaceutical company with a deep product pipeline, including two promising late-stage compounds, the most advanced of which is vilazodone, a new treatment in development for Major Depressive Disorder.

30 Dec 2010

Dosing initiated in combination Phase I study of palifosfamide with etoposide and cisplatin/carboplatin in SCLC

ZIOPHARM Oncology, Inc., announced today that the first patient has been dosed in a Phase I, single arm, dose escalation study at the Indiana University Cancer Center of intravenous (IV) palifosfamide (ZIO-201) in combination with etoposide (VP-16) and cisplatin/carboplatin (platinum) in the treatment of small cell lung cancer (SCLC) and other cancers.

29 Dec 2010

Centocor Ortho Biotech files REMICADE sBLA for ulcerative colitis in pediatric patients

Centocor Ortho Biotech Inc. announced today that it has filed a supplemental Biologics License Application (sBLA) with the U.S. Food and Drug Administration (FDA) requesting the approval of REMICADE® (infliximab) for the treatment of moderately to severely active ulcerative colitis (UC) in pediatric patients who have had an inadequate response to conventional therapy.

29 Dec 2010

FDA approves Endo's FORTESTA Gel for low testosterone

Endo Pharmaceuticals today announced that the U.S. Food and Drug Administration (FDA) has approved FORTESTA Gel for the treatment of low testosterone, or 'Low T,' also known as hypogonadism. Symptoms associated with Low T include erectile dysfunction and decreased sexual desire, fatigue and loss of energy, mood depression, regression of secondary sexual characteristics and osteoporosis.

29 Dec 2010

CFTR protein regulates inflammation and cell death in emphysema, chronic lung diseases

A team of Johns Hopkins Children's Center researchers has discovered that a protein involved in cystic fibrosis also regulates inflammation and cell death in emphysema and may be responsible for other chronic lung diseases.

29 Dec 2010

Myrexis initiates controlled two-arm Azixa Phase 2b clinical study in glioblastoma multiforme

EpiCept Corporation today reported that Myrexis, Inc. has initiated a controlled two-arm Phase 2b clinical study of Azixa™ as a front-line treatment for glioblastoma multiforme (GBM). Azixa™, a vascular disruption agent with potent anti-cancer activity, was discovered by EpiCept as part of its ASAP technology platform and licensed to Myrexis.

28 Dec 2010

Emergent initiates AV7909 Phase I trail for Anthrax vaccine

Emergent BioSolutions today announced the initiation of a Phase I clinical trial for NuThraxTM, also known as AV7909, with the dosing of the first subject.

27 Dec 2010

Cancer survival rates improving

Survival rates for cancers of the bowel, breast, lung and ovary that were diagnosed between 1995 and 2007 were compared between Australia, Canada, Denmark, Norway, Sweden and the UK. Overall, survival rates improved in all six countries. However, survival was found to be “persistently lower” in Denmark, England, Northern Ireland and Wales. This was particularly the case after the first year of diagnosis and for patients aged 65 and over. In UK cancer survival rates have improved significantly. Breast cancer survival at five years, for example, increased from 74.8% in 1995-9, to 81.6% in 2005-7. Despite this, the UK still has the lowest breast cancer survival rate at five years.

27 Dec 2010

New derivation of stem cells from fat cells hold promise for therapeutic, cosmetic benefits

Two studies appearing in the current issue of Cell Transplantation 19(10) discuss stem cells derived from adipose (fat) cells and their potential use in plastic surgery and tissue reconstruction. The studies are now freely available on-line at http://www.ingentaconnect.com/content/cog/ct/ .

24 Dec 2010

Growth hormone may be hazardous for middle aged and older people

A compound which acts in the opposite way as growth hormone can reverse some of the signs of aging, a research team that includes a Saint Louis University physician has shown. The finding may be counter-intuitive to some older adults who take growth hormone, thinking it will help revitalize them.

24 Dec 2010

Quercetin and resveratrol may play an important role in inflammation and insulin resistance

A study was carried out to examine the extent to which quercetin and trans-resveratrol (RSV) prevented inflammation or insulin resistance in primary cultures of human adipocytes treated with tumor necrosis factor-a (TNF-a)-an inflammatory cytokine elevated in the plasma and adipose tissue of obese, diabetic individuals. Cultures of human adipocytes were pretreated with quercetin and trans-RSV followed by treatment with TNF-a. Subsequently, gene and protein markers of inflammation and insulin resistance were measured.

24 Dec 2010

Sequestering GSK3 enzyme leads to stabilization of proteins in cells

The cell signaling pathway known as Wnt, commonly activated in cancers, causes internal membranes within a healthy cell to imprison an enzyme that is vital in degrading proteins, preventing the enzyme from doing its job and affecting the stability of many proteins within the cell, researchers at UCLA's Jonsson Comprehensive Cancer Center have found.

24 Dec 2010

Target enrollment reached in belinostat Phase 2 study in Carcinoma of Unknown Primary

Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations with a primary focus in oncology, announced today that the target enrollment has been reached for the Phase 2 study of belinostat in Carcinoma of Unknown Primary (CUP).

23 Dec 2010

Oncology News and Research

Further Reading

MGH, Veridex establish research center of excellence on circulating tumor cell technologies

CDK1 protein deactivates EZH2 enzyme that causes cancer spread

Los Angeles Magazine declares LA BioMed physicians as 2011 Southern California Super Doctors

EDAP reduces outstanding debt by $4.6 million

EpiCept regains compliance with continued listing requirement of Nasdaq Capital Market

Children more likely to suffer from appendicitis in areas with few pediatricians

Enrollment commences in belinostat-Tarceva combination trial for NSCLC

Clinical Data closes sale of genetic, pharmacogenomic testing and biomarker development business

Dosing initiated in combination Phase I study of palifosfamide with etoposide and cisplatin/carboplatin in SCLC

Centocor Ortho Biotech files REMICADE sBLA for ulcerative colitis in pediatric patients

FDA approves Endo's FORTESTA Gel for low testosterone

CFTR protein regulates inflammation and cell death in emphysema, chronic lung diseases

Myrexis initiates controlled two-arm Azixa Phase 2b clinical study in glioblastoma multiforme

Emergent initiates AV7909 Phase I trail for Anthrax vaccine

Cancer survival rates improving

New derivation of stem cells from fat cells hold promise for therapeutic, cosmetic benefits

Growth hormone may be hazardous for middle aged and older people

Quercetin and resveratrol may play an important role in inflammation and insulin resistance

Sequestering GSK3 enzyme leads to stabilization of proteins in cells

Target enrollment reached in belinostat Phase 2 study in Carcinoma of Unknown Primary

Your guide to microplate readers for cancer research eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News